Takeda Alunbrig first-line treatment nSCLC efficacy actively delays disease progression in specific patients for more than 2 years

Globally, there are about 1.8 million new lung cancer cases each year, and NSCLC is the most common type of lung cancerIn NSCLC patients, 3-5% of patients carry ingress with the ALK gene are the main factors driving cancer development, and ALK inhibitors are particularly effective for themAlunbrig is the next generation of tyrosine kinase inhibitors (TKI) developed by Takeda, which are designed to target and inhibit ALK fusion proteinsIn April 2017, it received accelerated FDA approval to treat ALK-positive metastatic NSCLC patientsThese patients continued to progress after receiving crizotinib treatment275 PATIENTS WITH ALK-positive advanced or metastatic NSCLC were treated with Alunbrig or crizotinib in an open label called ALTA-1L, a randomized multicenter Phase 3 clinical trialThe patient was not previously treated with ALK inhibitorsThe results showed that the non-progressive life span (PFS) in patients in the Alunbrig group was 29.4 months, compared with 9.2 months in the active control groupFor patients with brain metastasis, PFS in the Alunbrig group was 24 months and the active control group was 5.6 monthsAlunbrig also significantly improves the quality of life of patientsDr Phil Rowlands, head of oncology at, said: "We are proud of the progress we have madeThe results of the ALTA-1L clinical trial showed that Alunbrig was able to delay disease progression by more than two years and significantly reduce the risk of disease progression in patients with brain metastatic tumorsWe look forward to submitting this data to global regulators in an effort to benefit Alunbrig patients with a global ALK-positive NSCLCReferences:®OriginD November 24, 2019, from https://original title: Express delivery - delay the progression of a particular lung cancer patient for more than 2 years! Takeda ALK inhibitors have positive long-term efficacy